Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 2 of 2 entries
Sorted by: Best Match Show Resources per page
Dynamic kinetic resolution of beta-azido alcohols. An efficient route to chiral aziridines and beta-amino alcohols.

The Journal of organic chemistry

Pàmies O, Bäckvall JE.
PMID: 11375029
J Org Chem. 2001 Jun 01;66(11):4022-5. doi: 10.1021/jo015579d.

Enzymatic resolution of beta-azido alcohols in combination with ruthenium-catalyzed alcohol isomerization led to a successful dynamic kinetic resolution. A variety of racemic beta-azido alcohols were efficiently transformed to the corresponding enantiomerically pure acetates (ee up to 99% and conversion...

Cite
Pàmies O, Bäckvall JE. Dynamic kinetic resolution of beta-azido alcohols. An efficient route to chiral aziridines and beta-amino alcohols. J Org Chem. 2001;66(11):4022-5doi: 10.1021/jo015579d.
Pàmies, O., & Bäckvall, J. E. (2001). Dynamic kinetic resolution of beta-azido alcohols. An efficient route to chiral aziridines and beta-amino alcohols. The Journal of organic chemistry, 66(11), 4022-5. https://doi.org/10.1021/jo015579d
Pàmies, O, and Bäckvall, J E. "Dynamic kinetic resolution of beta-azido alcohols. An efficient route to chiral aziridines and beta-amino alcohols." The Journal of organic chemistry vol. 66,11 (2001): 4022-5. doi: https://doi.org/10.1021/jo015579d
Pàmies O, Bäckvall JE. Dynamic kinetic resolution of beta-azido alcohols. An efficient route to chiral aziridines and beta-amino alcohols. J Org Chem. 2001 Jun 01;66(11):4022-5. doi: 10.1021/jo015579d. PMID: 11375029.
Copy Download .nbib Format: NLM
Screening of Clinically Approved and Investigation Drugs as Potential Inhibitors of SARS-CoV-2: A Combined in silico and in vitro Study.

Molecular informatics

Durdagi S, Orhan MD, Aksoydan B, Calis S, Dogan B, Sahin K, Shahraki A, Iyison NB, Avsar T.
PMID: 34529322
Mol Inform. 2021 Sep 16;e2100062. doi: 10.1002/minf.202100062. Epub 2021 Sep 16.

In the current study, we used 7922 FDA approved small molecule drugs as well as compounds in clinical investigation from NIH's NPC database in our drug repurposing study. SARS-CoV-2 main protease as well as Spike protein/ACE2 targets were used...

Cite
Durdagi S, Orhan MD, Aksoydan B, et al. Screening of Clinically Approved and Investigation Drugs as Potential Inhibitors of SARS-CoV-2: A Combined in silico and in vitro Study. Mol Inform. 2021;e2100062doi: 10.1002/minf.202100062.
Durdagi, S., Orhan, M. D., Aksoydan, B., Calis, S., Dogan, B., Sahin, K., Shahraki, A., Iyison, N. B., & Avsar, T. (2021). Screening of Clinically Approved and Investigation Drugs as Potential Inhibitors of SARS-CoV-2: A Combined in silico and in vitro Study. Molecular informatics, e2100062. https://doi.org/10.1002/minf.202100062
Durdagi, Serdar, et al. "Screening of Clinically Approved and Investigation Drugs as Potential Inhibitors of SARS-CoV-2: A Combined in silico and in vitro Study." Molecular informatics vol. (2021): e2100062. doi: https://doi.org/10.1002/minf.202100062
Durdagi S, Orhan MD, Aksoydan B, Calis S, Dogan B, Sahin K, Shahraki A, Iyison NB, Avsar T. Screening of Clinically Approved and Investigation Drugs as Potential Inhibitors of SARS-CoV-2: A Combined in silico and in vitro Study. Mol Inform. 2021 Sep 16;e2100062. doi: 10.1002/minf.202100062. Epub 2021 Sep 16. PMID: 34529322; PMCID: PMC8646260.
Copy Download .nbib Format: NLM
Showing 1 to 2 of 2 entries